Advanced search
1 file | 988.31 KB

The ReNAissanCe of mRNA-based cancer therapy

(2015) EXPERT REVIEW OF VACCINES. 14(2). p.235-251
Author
Organization
Abstract
About 25 years ago, mRNA became a tool of interest in anticancer vaccination approaches. However, due to its rapid degradation in situ, direct application of mRNA was confronted with considerable skepticism during its early use. Consequently, mRNA was for a long time mainly used for the ex vivo transfection of dendritic cells, professional antigen-presenting cells known to stimulate immunity. The interest in direct application of mRNA experienced a revival, as researchers became aware of the many advantages mRNA offers. Today, mRNA is considered to be an ideal vehicle for the induction of strong immune responses against cancer. The growing numbers of preclinical trials and as a consequence the increasing clinical application of mRNA as an off-the-shelf anticancer vaccine signifies a renaissance for transcript-based antitumor therapy. In this review, we highlight this renaissance using a timeline providing all milestones in the application of mRNA for anticancer vaccination.
Keywords
FLT3 LIGAND, IN-VIVO, LENGTH TUMOR-ANTIGENS, CYTOTOXIC T-LYMPHOCYTES, DENDRITIC CELL VACCINATION, dendritic cell, cancer, immunotherapy, COLONY-STIMULATING FACTOR, vaccine, MELANOMA PATIENTS, ANTITUMOR IMMUNITY, DIRECT-INJECTION, CTL RESPONSES

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 988.31 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Van Lint, Sandra, Dries Renmans, Katrijn Broos, Heleen Dewitte, Ine Lentacker, Carlo Heirman, Karine Breckpot, and Kris Thielemans. 2015. “The ReNAissanCe of mRNA-based Cancer Therapy.” Expert Review of Vaccines 14 (2): 235–251.
APA
Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., et al. (2015). The ReNAissanCe of mRNA-based cancer therapy. EXPERT REVIEW OF VACCINES, 14(2), 235–251.
Vancouver
1.
Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C, et al. The ReNAissanCe of mRNA-based cancer therapy. EXPERT REVIEW OF VACCINES. 2015;14(2):235–51.
MLA
Van Lint, Sandra, Dries Renmans, Katrijn Broos, et al. “The ReNAissanCe of mRNA-based Cancer Therapy.” EXPERT REVIEW OF VACCINES 14.2 (2015): 235–251. Print.
@article{5875658,
  abstract     = {About 25 years ago, mRNA became a tool of interest in anticancer vaccination approaches. However, due to its rapid degradation in situ, direct application of mRNA was confronted with considerable skepticism during its early use. Consequently, mRNA was for a long time mainly used for the ex vivo transfection of dendritic cells, professional antigen-presenting cells known to stimulate immunity. The interest in direct application of mRNA experienced a revival, as researchers became aware of the many advantages mRNA offers. Today, mRNA is considered to be an ideal vehicle for the induction of strong immune responses against cancer. The growing numbers of preclinical trials and as a consequence the increasing clinical application of mRNA as an off-the-shelf anticancer vaccine signifies a renaissance for transcript-based antitumor therapy. In this review, we highlight this renaissance using a timeline providing all milestones in the application of mRNA for anticancer vaccination.},
  author       = {Van Lint, Sandra and Renmans, Dries and Broos, Katrijn and Dewitte, Heleen and Lentacker, Ine and Heirman, Carlo and Breckpot, Karine and Thielemans, Kris},
  issn         = {1476-0584},
  journal      = {EXPERT REVIEW OF VACCINES},
  keyword      = {FLT3 LIGAND,IN-VIVO,LENGTH TUMOR-ANTIGENS,CYTOTOXIC T-LYMPHOCYTES,DENDRITIC CELL VACCINATION,dendritic cell,cancer,immunotherapy,COLONY-STIMULATING FACTOR,vaccine,MELANOMA PATIENTS,ANTITUMOR IMMUNITY,DIRECT-INJECTION,CTL RESPONSES},
  language     = {eng},
  number       = {2},
  pages        = {235--251},
  title        = {The ReNAissanCe of mRNA-based cancer therapy},
  url          = {http://dx.doi.org/10.1586/14760584.2015.957685},
  volume       = {14},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: